Please use this identifier to cite or link to this item:
|Title:||Characterization of Campylobacter jejuni DNA gyrase as the target of quinolones|
Rakuno Gakuen University
Kissei Pharmaceutical Co., Ltd.
National Institute of Infectious Diseases
|Citation:||Journal of Infection and Chemotherapy. Vol.21, No.8 (2015), 604-609|
|Abstract:||© 2015 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Quinolones have long been used as the first-line treatment for Campylobacter infections. However, an increased resistance to quinolones has raised public health concerns. The development of new quinolone-based antibiotics with high activity is critical for effective, as DNA gyrase, the target of quinolones, is an essential enzyme for bacterial growth in several mechanisms. The evaluation of antibiotic activity against Campylobacter jejuni largely relies on drug susceptibility tests, which require at least 2 days to produce results. Thus, an invitro method for studying the activity of quinolones against the C.jejuni DNA gyrase is preferred. To identify potent quinolones, we investigated the interaction of C.jejuni DNA gyrase with a number of quinolones using recombinant subunits. The combination of purified subunits exhibited DNA supercoiling activity in an ATP dependent manner. Drug concentrations that inhibit DNA supercoiling by 50% (IC50s) of 10 different quinolones were estimated to range from 0.4 (sitafloxacin) to >100μg/mL (nalidixic acid). Sitafloxacin showed the highest inhibitory activity, and the analysis of the quinolone structure-activity relationship demonstrated that a fluorine atom at R-6 might play the important role in the inhibitory activity against C.jejuni gyrase. Measured quinolone IC50s correlated well with minimum inhibitory concentrations (R=0.9943). These suggest that the invitro supercoiling inhibition assay on purified recombinant C.jejuni DNA gyrase is a useful and predictive technique to monitor the antibacterial potency of quinolones. And furthermore, these data suggested that sitafloxacin might be a good candidate for clinical trials on campylobacteriosis.|
|Appears in Collections:||Scopus 2011-2015|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.